PHILADELPHIA--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of data using the Swoop system to image patients with Alzheimer’s disease including initial data from the CARE PMR study. The data was presented at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia from July 28 to August 1.
The CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study is a collection of data from multiple sites assessing the clinical utility and workflow benefits of using Swoop® system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy. These investigator-initiated observational studies aim to provide insights into the potential of ultra-low-field, portable MR brain imaging to enhance care for patients with Alzheimer's disease across many sites of care.
At the conference, researchers from Washington University in St. Louis, a center actively enrolling patients in the CARE PMR study, presented a poster titled "Advanced Imaging Modalities for ARIA Detection and Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer's Disease: A Collaborative Prospective Study." The poster, authored by Jude-Patrick Nnamdi Okafor, MD, et al., reported data on sixteen patients. Notably, one participant exhibited "evidence of hyperintensity on FLAIR, consistent with ARIA-E,” which was deemed “well detected at low field strength.”
Ad Statistics
Times Displayed: 12806
Times Visited: 23 Final days to save an extra 10% on Imaging, Ultrasound, and Biomed parts web prices.* Unlimited use now through September 30 with code AANIV10 (*certain restrictions apply)
Researchers from Massachusetts General Hospital virtually presented a poster titled "Portable, Low-field MRI for Alzheimer’s Disease," authored by W. Taylor Kimberly, MD, PhD, et al. This poster focused on the quantitative assessment of ultra-low-field MRI images compared to conventional high-field MR images in evaluating brain morphometry in Alzheimer's patients. The study highlighted a strong agreement in volumes between conventional high-field MR images and low-field MR images. The poster concluded, “Given its portability and low operational cost, [low-field] MRI holds promise as a valuable tool to diagnose [Alzheimer's disease] and monitor its progression.”
Dr. Edmond Knopp, Vice President of Medical Affairs at Hyperfine, commented, “The impressive image quality achieved with our ultra-low-field MRI technology opens up the potential to provide critical diagnostic information for patients with Alzheimer's disease across many sites of care, including infusion centers and clinics that currently cannot offer on-site imaging capabilities. These posters provide early evidence that portable MRI could transform Alzheimer's disease management.”
